Treanda regulatory update

FDA approved an sNDA from Teva for a new liquid formulation of Treanda bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin's lymphoma (NHL). Teva said the liquid formulation of the alkylating agent removes the step of reconstituting lyophilized powder with sterile water prior to adding to the diluent and administering it to patients. Cephalon Corp., which Teva acquired, markets Treanda in the U.S. ...